← All diseases
Blood and bone marrow
Myelofibrosis
Do you want to receive a message when there is new research on Myelofibrosis? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, one sentence explaining what was investigated appears above each publication — and you receive a message as soon as there is new research on Myelofibrosis. View what Premium costs.
Publications and studies (1631)
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Successful treatment of idiopathic multicentric Castleman disease with TAFRO and kidney involvement: case report and literature review. (2026/12/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Primary Myelofibrosis (PMF)-The German ONKOPEDIA Guideline 2025. (2026/10/01) ♡
- Treatment guidelineiAn official agreement between doctors about how this disease should be treated. This is not a single study but the conclusion of an entire medical field. The German ONKOPEDIA Guideline for Myelofibrosis in 2025-Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO). (2026/10/01) ♡
- Matching-Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second-Line Myelofibrosis Therapy. (2026/09/01) ♡
- A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib. (2026/08/11) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. First Philippine report of myeloproliferative neoplasms with concurrent JAK2 and BCR::ABL1 mutations. (2026/08/10) ♡
- Evaluation of the frequency, risk factors, and outcomes of splanchnic vein thrombosis in myeloproliferative neoplasms: a retrospective cohort study. (2026/08/07) ♡
- A phase II study of low dose melphalan with thiotepa and fludarabine as preparative regimen for alternative donor transplantation. (2026/08/07) ♡
- Prognostic factors for early mortality following allogeneic hematopoietic cell transplantation in hematologic malignancies. (2026/08/07) ♡
- Lysozyme-associated nephropathy heralding leukemic transformation in myelofibrosis. (2026/08/06) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Photodynamic Therapy as a Key Adjunct in the Multimodal Management of Cutaneous Fusarium solani Infection in an Immunocompromised Patient: A Case Report. (2026/08/04) ♡
- Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era. (2026/08/04) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Type II JAK2 Inhibitor Gets Off to a Strong Start. (2026/08/03) ♡
- Non-invasive multiparametric characterization of essential thrombocythemia, premyelofibrosis, and overt myelofibrosis. (2026/08/03) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Spatially resolved transcriptomic profiling of myelofibrosis spleen reveals compartment specific niche programs. (2026/08/03) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Management of BK Polyomavirus in a Kidney Transplant Recipient With Primary Myelofibrosis on JAK-2 Inhibition - A Case Report and Literature Review. (2026/07/31) ♡
- Perioperative management of ruxolitinib in primary myelofibrosis during coronary artery bypass graft surgery. (2026/07/30) ♡
- Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial. (2026/07/30) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Autoimmune myelofibrosis secondary to systemic lupus erythematosus: a diagnostic challenge in a resource-limited setting. (2026/07/27) ♡
- Biochemical Predictors and Clinical Characteristics for the Development of Cytopenia and Bone Marrow Involvement Among Patients With Primary Hyperparathyroidism. (2026/07/27) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Selinexor for myelofibrosis or a drug in search of a disease? (2026/07/25) ♡
- DNMT3A and TET2 Mutations are Associated With Both Venous Thrombosis and Major Bleeding in Patients With Polycythemia Vera and Essential Thrombocythemia. (2026/07/23) ♡
- Extramedullary Hematopoiesis of the Breast. (2026/07/22) ♡
- Peri-Transplant Ruxolitinib Prophylaxis Improves Outcome in Patients Receiving Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis. (2026/07/22) ♡
- Disease Burden, Inadequate Hematocrit Control, and Thromboembolic Events in Patients with Polycythemia Vera Despite Current Standard of Care Treatment: A Retrospective Claims Study. (2026/07/22) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Practical Guide for Managing Philadelphia-Negative Myeloproliferative Neoplasms in Patients with Organ Dysfunction. (2026/07/21) ♡
- Risk factors associated with high probability of pulmonary hypertension in patients with myeloproliferative neoplasms. (2026/07/21) ♡
- Heme oxygenase-1/CO signaling suppresses NLRP3 inflammasome-mediated stromal fibrosis in primary myelofibrosis. (2026/07/20) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Lymphodepletion and donor lymphocyte infusions (LD-DLI) for DLI-non responsive myelofibrosis. (2026/07/20) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors. (2026/07/20) ♡
- Symptomatic Osteoarthritis May Be Associated with Higher Symptom Burden and Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Prospective Two-Centre Study. (2026/07/19) ♡
- Philadelphia-negative myeloproliferative neoplasms and acquired von Willebrand syndrome: only pertinent at diagnosis? (2026/07/17) ♡
- The thrombopoietin receptor in myeloproliferative neoplasms: A unifying mechanism of disease pathogenesis and therapeutic targeting. (2026/07/17) ♡
- Peribiliary Inflammatory Phlegmon Masquerading as Cholangiocarcinoma in Janus Kinase 2 V617F-positive Primary Myelofibrosis: A Multimodality Imaging Diagnosis. (2026/07/15) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Precision medicine in myelofibrosis: from molecular profiling to personalized therapy. (2026/07/15) ♡
- Fedratinib induces non-classical G2/M arrest via mitotic-kinase inhibition and synergizes with mitomycin C to suppress pancreatic ductal adenocarcinoma. (2026/07/14) ♡
- Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment-related pathways. (2026/07/14) ♡
- Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY-1 and MOMENTUM Trials. (2026/07/14) ♡
- Extramedullary Hematopoiesis in the Cerebral Dura Resulting in Fatal Brain Herniation in a Patient With Secondary Myelofibrosis: A Case Report. (2026/07/14) ♡
- Dosimetric evaluation and benchmarking of proton beam delivery methods in heterogeneous phantoms using the PHITS Monte Carlo code. (2026/07/14) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Myelofibrosis treatment sequencing: mutation-informed risk and optimal JAK inhibitor discontinuation. (2026/07/13) ♡
- Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia. (2026/07/13) ♡
- Masked polycythemia vera presenting as non-cirrhotic portal hypertension with isolated gastric varices: a case report. (2026/07/13) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. RSK signaling in myeloid malignancies: biology, disease dependency, and therapeutic targeting. (2026/07/10) ♡
- Glutamate accumulation in myelofibrosis microenvironment rewires mesenchymal stromal cells metabolic and epigenetic profiles. (2026/07/09) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The inflammatory/fibrotic axis across organs: myelofibrosis as a model of reversibility. (2026/07/08) ♡
- Fish-shaped erythrocytes and pincer cells co-occur in distinct hematological disorders and are associated with anemia severity. (2026/07/07) ♡
- Splenic radiotherapy before allogeneic transplantation for myelofibrosis. (2026/07/07) ♡
- Immune Effector Cell-Associated Hematotoxicity With Secondary Myelofibrosis Following Idecabtagene-Vicleucel for Multiple Myeloma, Comprehensively Treated With Autologous Hematopoietic Stem Cell Boosting. (2026/07/06) ♡
- Comparative Value of the Novel Age-Agnostic DIPSS-R Versus the DIPSS for Prognostication in Myelofibrosis: A Multicenter Evaluation and Reclassification Study. (2026/07/05) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.